PHARMASCROLL
enquiry@pharmascroll.com Mail Us
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
PHARMASCROLL
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
    • TreasureTell
  • Social Media Analytics
    • SocialBI
  • Market Research Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
enquiry@pharmascroll.com Mail Us
HomeNewsOncology
  • Venclexta/Venclyxto improved overall survival in previously untreated AML patients

    • March 26, 2020
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Post-HSCT Cyclophosphamide use Improves Transplantation Outcomes for AML/MDS

    • March 22, 2020
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • FDA approves Opdivo® + Yervoy® for HCC patients previously treated with sorafenib

    • March 22, 2020
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Shire Announces Sale of Oncology Business to Servier for $2.4 Billion to Focus on Rare Disease Leadership

    • April 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
Newsletter
Recent Posts
  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry
  • Role of Patient Insights in Building Strong Healthcare
  • Social Media Analytics in Healthcare
  • Importance of KOL Analytics in the Healthcare domain

Contact Us

   enquiry@pharmascroll.com
   +919311760222

   Indian Address: PhamaScroll Research and Consulting Private Limited, 91 Springboard, 4th floor, F948+W7, Laxmi Cyber City, Whitefields, Hyderabad, Telangana 500081

    US address: 12 Self Ct, Wallingford CT 06492

Recent Tweets

  • The FDA has approved Menarini's Orserdu (elacestrant) as a second-line treatment for advanced breast cancer with ES… https://t.co/vUiNkpOSQs3 hours ago
  • The European Commission approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for patients wit… https://t.co/huyODDdHeA4 days ago

Recent Posts

  • Predictive Analytics in Healthcare
  • Business Intelligence and Analytics in the Pharma Industry
  • Role of Patient Insights in Building Strong Healthcare

News Letter

© 2023 Copyright. All rights reserved

Catalyzed by

SPEAK TO AN EXPERT